Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 225

1.

Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.

Lin SF, Lin JD, Yeh CN, Huang YT, Chou TC, Wong RJ.

Endocr Relat Cancer. 2019 Jun 1. pii: ERC-18-0555.R2. doi: 10.1530/ERC-18-0555. [Epub ahead of print]

PMID:
31189135
2.

Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View.

Wu CE, Tzen CY, Wang SY, Yeh CN.

Cancers (Basel). 2019 May 16;11(5). pii: E679. doi: 10.3390/cancers11050679. Review.

3.

Natural Course of Acute Cholecystitis in Patients Treated With Percutaneous Transhepatic Gallbladder Drainage Without Elective Cholecystectomy.

Hung YL, Chong SW, Cheng CT, Liao CH, Fu CY, Hsieh CH, Yeh TS, Yeh CN, Jan YY, Wang SY.

J Gastrointest Surg. 2019 Apr 3. doi: 10.1007/s11605-019-04213-0. [Epub ahead of print]

PMID:
30945085
4.

Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome.

Wang SY, Wu CE, Lai CC, Chen JS, Tsai CY, Cheng CT, Yeh TS, Yeh CN.

Cancers (Basel). 2019 Mar 25;11(3). pii: E424. doi: 10.3390/cancers11030424.

5.

Interferon α-inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival.

Chiang KC, Huang ST, Wu RC, Huang SC, Yeh TS, Chen MH, Hsu JT, Chen LW, Kuo SF, Chueh HY, Juang HH, Hung SI, Yeh CN, Pang JS.

Cancer Manag Res. 2019 Feb 28;11:1893-1905. doi: 10.2147/CMAR.S196485. eCollection 2019.

6.

Preoperative tyrosine kinase inhibitors risks bowel anastomotic healing in patients with advanced primary and recurrent/metastatic gastrointestinal stromal tumors--- A rose has its thorns.

Lee JC, Chen CH, Chen TC, Yeh CN, Yeh TS.

Eur J Surg Oncol. 2019 Feb;45(2):153-159. doi: 10.1016/j.ejso.2018.09.029. Epub 2018 Oct 17.

PMID:
30712551
7.

mTOR Inhibitors in Advanced Biliary Tract Cancers.

Wu CE, Chen MH, Yeh CN.

Int J Mol Sci. 2019 Jan 24;20(3). pii: E500. doi: 10.3390/ijms20030500. Review.

8.

Binder-free graphene oxide doughs.

Yeh CN, Huang H, Lim ATO, Jhang RH, Chen CH, Huang J.

Nat Commun. 2019 Jan 24;10(1):422. doi: 10.1038/s41467-019-08389-6.

9.

HO-1 is a favorable prognostic factor for HBV-HCC patients who underwent hepatectomy.

Yeh CN, Wu RC, Cheng CT, Tsai CY, Chang YR, Yeh TS, Wu TH, Lee WC, Chiang KC.

Cancer Manag Res. 2018 Nov 21;10:6049-6059. doi: 10.2147/CMAR.S186931. eCollection 2018.

10.

Characterization of intrahepatic cholangiocarcinoma after curative resection: outcome, prognostic factor, and recurrence.

Chan KM, Tsai CY, Yeh CN, Yeh TS, Lee WC, Jan YY, Chen MF.

BMC Gastroenterol. 2018 Dec 4;18(1):180. doi: 10.1186/s12876-018-0912-x.

11.

Surgical Margin Status of Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgery with Radical Intent: Risk Factors for the Survival Impact of Positive Margins.

Lai CC, Wang SY, Liao CH, Hsu JT, Chiang KC, Yeh TS, Hwang TL, Yeh CN.

In Vivo. 2018 Nov-Dec;32(6):1591-1597. doi: 10.21873/invivo.11419.

12.

CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery.

Hsu CP, Lee LY, Hsu JT, Hsu YP, Wu YT, Wang SY, Yeh CN, Chen TC, Hwang TL.

In Vivo. 2018 Nov-Dec;32(6):1533-1540. doi: 10.21873/invivo.11411.

13.

Over-expression of TNNI3K is associated with early-stage carcinogenesis of cholangiocarcinoma.

Yeh CN, Chen MH, Chang YC, Wu RC, Tsao LC, Wang SY, Cheng CT, Chiang KC, Chen TW, Hsiao M, Weng WH.

Mol Carcinog. 2019 Feb;58(2):270-278. doi: 10.1002/mc.22925. Epub 2018 Nov 8.

PMID:
30334579
14.

Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.

Hsu CL, Lui KW, Chi LM, Kuo YC, Chao YK, Yeh CN, Lee LY, Huang Y, Lin TL, Huang MY, Lai YR, Yeh YM, Fan HC, Lin AC, Lu YJ, Hsieh CH, Chang KP, Tsang NM, Wang HM, Chang AY, Chang YS, Li HP.

J Exp Clin Cancer Res. 2018 Sep 20;37(1):233. doi: 10.1186/s13046-018-0873-5.

15.

Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors.

Chen JS, Yeh CN, Cheng CT, Yen CC, Chen YY, Huang SC, Chiang KC, Yeh TS, Chen SC, Chao TC, Yang MH, Chao Y.

Oncol Lett. 2018 Sep;16(3):3070-3082. doi: 10.3892/ol.2018.9003. Epub 2018 Jun 21.

16.

Response letter on Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib-new ammunition in battling exon 17 mutations.

Yeh CN.

Transl Gastroenterol Hepatol. 2018 Jun 19;3:33. doi: 10.21037/tgh.2018.06.03. eCollection 2018. No abstract available.

17.

MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.

Cheng CT, Chen YY, Wu RC, Tsai CY, Chiang KC, Yeh TS, Chen MH, Yeh CN.

Oncol Rep. 2018 Sep;40(3):1411-1421. doi: 10.3892/or.2018.6543. Epub 2018 Jul 4.

PMID:
30015968
18.

The Role of Noncontrast CT in the Evaluation of Surgical Abdomen Patients.

Li PH, Tee YS, Fu CY, Liao CH, Wang SY, Hsu YP, Yeh CN, Wu EH.

Am Surg. 2018 Jun 1;84(6):1015-1021.

PMID:
29981641
19.

MART-10, a 1α,25(OH)2D3 Analog, Potently Represses Metastasis of ER+ Breast Cancer Cells with VEGF-A Overexpression.

Chiang KC, Yeh CN, Yeh TS, Juang HH, Chen LW, Kuo SF, Chen MH, Chen TC, Takano M, Kittaka A, Pang JS.

Anticancer Res. 2018 Jul;38(7):3879-3887. doi: 10.21873/anticanres.12672.

PMID:
29970508
20.

Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma.

Chang PM, Cheng CT, Wu RC, Chung YH, Chiang KC, Yeh TS, Liu CY, Chen MH, Chen MH, Yeh CN.

Oncol Lett. 2018 Jul;16(1):566-572. doi: 10.3892/ol.2018.8690. Epub 2018 May 10.

Supplemental Content

Support Center